Aggressive Lymphomas
Feature
New BTK inhibitor under review in China
Zanubrutinib is being reviewed for treatment of relapsed/refractory mantle cell lymphoma.
News
NICE says CAR T-cell therapy isn’t cost-effective
The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending against the use of axicabtagene ciloleucel (...
Latest News
European Commission approves first CAR T-cell therapies
Tisagenlecleucel and axicabtagene ciloleucel can now be marketed throughout Europe.
News
EC approves CAR T-cell therapy for DLBCL, PMBCL
The European Commission (EC) has approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (Yescarta®) to treat two...
From the Journals
ctDNA predicts early outcomes in DLBCL
Adding measurements of circulating tumor DNA to established risk factors could help create a profile of an overall picture of likely outcomes.
News
EC approves CAR T-cell therapy for ALL, DLBCL
The European Commission (EC) has granted approval for tisagenlecleucel (Kymriah®), a chimeric antigen receptor (CAR) T-cell therapy targeting CD19...
News
FDA approves new use for ibrutinib in WM
The US Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica®) for use in combination with rituximab to treat adults with...
News
Combo produces high response rate in CLL
Bendamustine followed by obinutuzumab and venetoclax produces a high overall response rate in chronic lymphocytic leukemia (CLL), according to...
From the Journals
Combo treatment yields MRD-negative remissions in CLL
Researchers with the German CLL Study Group said the combination of obinutuzumab plus venetoclax achieved fast responses.
News
Signal strength tied to potency of CAR T-cell therapy
Investigators found that chimeric antigen receptor (CAR) T cells with stronger signaling capabilities were less effective against lymphoma cells...
News
Role of SES in childhood cancer survival disparities
Socioeconomic status (SES) may explain some racial/ethnic disparities in childhood cancer survival, according to new research. The study showed...